Study Confirms Long-term Efficacy and Safety
ZUG — Galderma has released new data confirming the efficacy of Nemolizumab in treating children aged 2 to 11 with moderate-to-severe atopic dermatitis. The study, presented at the 2026 American Academy of Dermatology Annual Meeting, shows significant reductions in skin lesions and itch lasting up to a year.
Nemolizumab, already approved for use in adults and adolescents, was shown to be well tolerated in younger patients, according to Galderma’s statement. Dr. Lawrence Eichenfield, a leading expert in pediatric dermatology, emphasised the benefits of the treatment in improving the quality of life for children suffering from this condition.
Clinical Study Details
The phase II study evaluated Nemolizumab’s pharmacokinetics, safety, and efficacy in children, revealing that the treatment led to substantial improvements in skin conditions as early as four weeks into the study. Christophe Piketty, Global Programme Head at Galderma, stated that these findings expand the drug’s evidence base, highlighting its potential to address an unmet need in pediatric dermatology.
Atopic dermatitis impacts up to 25% of children, with limited treatment options available. The study’s positive results underline Nemolizumab’s role in potentially filling this gap, offering a new avenue for managing the condition effectively over the long term.
In addition to addressing physical symptoms, Nemolizumab has been shown to improve psychological well-being in children, as the constant itch and discomfort associated with atopic dermatitis can significantly affect mental health. Parents of participating children reported improvements in sleep quality and overall happiness, further highlighting the multi-faceted benefits of the treatment.
Last updated: 4 April 2026, 6:38 pm
